Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
$10.09
+0.2%
$9.56
$8.06
$17.00
$134.62M1.6343,521 shs33,144 shs
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
$2.48
+3.3%
$3.04
$1.80
$7.93
$104.83M0.17264,044 shs216,755 shs
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
$4.53
-0.4%
$4.30
$3.62
$9.18
$33.24M0.652,057 shs27,501 shs
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
$3.03
+8.2%
$3.17
$1.60
$10.48
$108.03M1.35798,867 shs293,004 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
+0.35%+11.03%+4.24%+11.03%-39.74%
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
-2.83%+7.62%-14.59%-36.00%+239,999,900.00%
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
-0.22%-0.66%+3.41%+13.18%-21.59%
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
-3.65%-7.59%-16.17%-25.33%+35.27%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
1.4759 of 5 stars
3.50.00.00.00.63.30.0
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
1.2335 of 5 stars
3.70.00.00.00.90.00.0
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
4.0043 of 5 stars
3.23.00.04.60.62.50.6
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
1.6764 of 5 stars
3.61.00.00.01.20.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
3.00
Buy$39.00286.52% Upside
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
3.40
Buy$12.67410.75% Upside
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
2.33
Hold$39.50771.96% Upside
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
3.14
Buy$20.50576.57% Upside

Current Analyst Ratings Breakdown

Latest KZR, GLSI, TARA, and HURA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/23/2025
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
Brookline Capital Management
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/22/2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$21.00
5/16/2025
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
4/28/2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
4/21/2025
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$38.00 ➝ $39.00
4/16/2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Outperform$12.00
(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/A$0.19 per shareN/A
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
N/AN/AN/AN/A$0.34 per shareN/A
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
$7M4.73N/AN/A$16.02 per share0.28
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
N/AN/AN/AN/A$4.77 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$15.79M-$1.26N/AN/AN/AN/A-450.87%-333.18%8/12/2025 (Estimated)
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
-$21.68MN/A0.00N/AN/A291.69%122.09%N/A
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
-$83.74M-$10.82N/AN/AN/AN/A-61.15%-50.27%8/12/2025 (Estimated)
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
-$44.60M-$1.72N/AN/AN/AN/A-36.37%-33.29%8/5/2025 (Estimated)

Latest KZR, GLSI, TARA, and HURA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
-$0.43N/AN/AN/AN/AN/A
5/20/2025Q1 2025
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$0.24-$0.25-$0.01-$0.25N/AN/A
5/15/2025Q1 2025
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
-$0.13-$0.15-$0.02-$0.15N/AN/A
5/13/2025Q1 2025
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
-$2.56-$2.27+$0.29-$2.27N/AN/A
5/8/2025Q1 2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
-$0.47-$0.29+$0.18-$0.29N/AN/A
4/15/2025Q4 2024
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$0.21-$0.61-$0.40-$0.61N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/AN/A
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
N/AN/AN/AN/AN/A
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
N/AN/AN/AN/AN/A
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/A
1.91
1.91
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
N/A
3.00
3.00
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
0.04
7.09
7.09
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
N/A
18.03
18.03

Institutional Ownership

CompanyInstitutional Ownership
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
4.16%
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
0.62%
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
67.90%
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
38.13%

Insider Ownership

CompanyInsider Ownership
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
51.67%
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
0.20%
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
9.30%
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
12.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
313.37 million6.46 millionNot Optionable
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
N/A43.68 million43.59 millionN/A
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
607.31 million6.63 millionNot Optionable
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
3038.58 million33.76 millionOptionable

Recent News About These Companies

Protara Therapeutics, Inc. (TARA) - Yahoo Finance
Analysts Set Expectations for TARA FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Greenwich LifeSciences stock logo

Greenwich LifeSciences NASDAQ:GLSI

$10.09 +0.02 (+0.20%)
Closing price 04:00 PM Eastern
Extended Trading
$10.15 +0.06 (+0.59%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

TuHURA Biosciences stock logo

TuHURA Biosciences NASDAQ:HURA

$2.48 +0.08 (+3.33%)
Closing price 04:00 PM Eastern
Extended Trading
$2.48 0.00 (0.00%)
As of 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

Kezar Life Sciences stock logo

Kezar Life Sciences NASDAQ:KZR

$4.53 -0.02 (-0.44%)
As of 04:00 PM Eastern

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Protara Therapeutics stock logo

Protara Therapeutics NASDAQ:TARA

$3.03 +0.23 (+8.21%)
Closing price 04:00 PM Eastern
Extended Trading
$3.07 +0.04 (+1.32%)
As of 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.